# AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05840016/  
OnCo record `nct05840016` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ivonescimab, Carboplatin, Tislelizumab in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.

## Summary

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05840016 by Akeso, with 532 participants enrolled, started 2023-08-17 and due to reach its primary completion in 2025-02-28. Interventions recorded: AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel. Conditions listed: Advanced Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05840016
- Phase: 3
- Setting: A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Combined With Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer
- Sponsor: Akeso
- Enrolled: 532

## Sources

- ClinicalTrials.gov NCT05840016: https://clinicaltrials.gov/study/NCT05840016

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05840016.json